Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nanostart AG announces record numbers for the first half of 2010

Abstract:
Transparency report in accordance with §17 Section 2 of the general terms and conditions for open markets

* Best first half of year in company history
* Net asset value increases to nearly EUR 144 million
* Cash influx from BioMicro transaction not yet included

Nanostart AG announces record numbers for the first half of 2010

Frankfurt am Main | Posted on September 21st, 2010

Frankfurt-based nanotechnology company Nanostart AG is reporting the best first-half results since the company was founded for the first six months of 2010. In accordance with commercial code, semi-annual net profit totaled EUR 923,000 (previous year EUR -1.4 million). Earlier in the year, Swiss company and global market leader Roche Diagnostics purchased the main product line of American Nanostart holding BioMicro Systems, Inc. Revenues from this transaction are however not included in semi-annual numbers, as the cash transfer took place after the June 30, 2010 reporting date.

In addition to positive earnings results, Nanostart achieved a net asset value of nearly EUR 144 million as of the reporting date. This is approximately EUR 29 million more than at the same point last year. In the conservative calculation of net asset value, shares of unlisted shareholdings - about 80 percent of the current portfolio - are attributed to acquisition costs in the calculations. Only existing shareholdings in Nanostart AG companies that are listed on the stock exchange are entered at market value.

The company continues to pursue international expansion. Acquisition of additional holdings is anticipated this year, especially in Singapore, where Nanostart is investing as a government partner.

Semi-annual numbers are now archived at the Nanostart website in the Investor Relations area. The 2010 semi-annual report will be available September 27 in the company reports section.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan. If there is any inconsistency between the German and the English versions of this document, the German version will prevail.

####

About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project